DYNC1I2: A Drug Target / Disease Biomarker (G1781)

Target Name: DYNC1I2

NCBI ID: G1781

DYNC1I2

DYNC1I2: A Drug Target / Disease Biomarker

DYNC1I2 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a key regulator of cell division and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of DYNC1I2 is its role in cell division. DYNC1I2 is a transcription factor that regulates the production of repetitive DNA sequences, which are used to create copies of the protein. It is also involved in the regulation of cell growth and the establishment of cell-cell adhesion.

In addition to its role in cell division, DYNC1I2 is also involved in the regulation of gene expression. It has been shown to play a role in the regulation of various gene expression pathways, including those involved in cell adhesion, migration, and invasion.

DYNC1I2 has also been implicated in a number of diseases and disorders. For example, it has been shown to be involved in the development and progression of cancer, particularly of ovarian and breast cancer. It has also been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its involvement in disease, DYNC1I2 is also a potential drug target. Researchers have identified several small molecules that have been shown to interact with DYNC1I2 and are being investigated as potential therapeutic agents. These molecules include inhibitors of DNA replication, inhibitors of transcription factor activity, and modulators of ion channels.

One of the most promising potential drug targets for DYNC1I2 is an inhibitor of DNA replication. Studies have shown that inhibitors of DNA replication can have a beneficial effect on the treatment of cancer, particularly in cases where the disease has resistance to traditional therapies.

Another potential drug target for DYNC1I2 is an inhibitor of transcription factor activity. Studies have shown that inhibitors of transcription factor activity can have a beneficial effect on the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, DYNC1I2 is also a valuable biomarker for a number of diseases. For example, it has been shown to be a useful biomarker for the diagnosis of cancer, particularly of ovarian and breast cancer. It is also a useful biomarker for tracking the effectiveness of anti-neoplasic therapies and for identifying potential drug targets for cancer.

Overall, DYNC1I2 is a protein that has important roles in cell division and gene expression, and is involved in the development and progression of a number of diseases and disorders. As a potential drug target, it is a promising area for future research and the development of new therapeutic agents.

Protein Name: Dynein Cytoplasmic 1 Intermediate Chain 2

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function (PubMed:31079899). Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules (PubMed:31079899). The intermediate chains mediate the binding of dynein to dynactin via its 150 kDa component (p150-glued) DCTN1 (By similarity). Involved in membrane-transport, such as Golgi apparatus, late endosomes and lysosomes (By similarity)

The "DYNC1I2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC1I2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets